{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T11:38:22Z","timestamp":1784115502400,"version":"3.55.0"},"reference-count":31,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T00:00:00Z","timestamp":1540252800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Isfahan Endocrine and Metabolism Research Center, Isfahan University of Medical Sciences","award":["1395.3.292"],"award-info":[{"award-number":["1395.3.292"]}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J of Diabetes Invest"],"published-print":{"date-parts":[[2019,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Aims\/Introduction<\/jats:title><jats:p>Postmenopausal women receive bisphosphonates for osteoporosis treatment. The effect of these medications on developing diabetes mellitus in prediabetic patients is yet to be investigated. We aimed to determine the effect of alendronate on plasma glucose, insulin indices of postmenopausal women with prediabetes and osteopenia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and Methods<\/jats:title><jats:p>The present triple\u2010blind randomized controlled clinical trial included 60 postmenopausal women, aged 45\u201360\u00a0years. All patients were vitamin\u00a0D sufficient. They were randomly enrolled in intervention (70\u00a0mg\/week alendronate for 12\u00a0weeks) and control (placebo tablet per week for 12\u00a0weeks) groups. The morning 8\u2010h fasting blood samples were collected at the baseline and follow\u2010up visits to measure the fasting plasma glucose (mg\/<jats:styled-content style=\"fixed-case\">dL<\/jats:styled-content>), insulin and hemoglobin A1c (HbA1c). Plasma glucose and insulin concentration were measured 30, 60 and 120\u00a0min after the glucose tolerance test. The Matsuda Index, homeostasis model assessment of insulin resistance, homeostasis model assessment of \u03b2\u2010cell function and the area under the curves of glucose and insulin were calculated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The mean (standard deviation) fasting plasma glucose (102.43 [1.46] mg\/<jats:styled-content style=\"fixed-case\">dL<\/jats:styled-content> vs 94.23 [1.17] mg\/<jats:styled-content style=\"fixed-case\">dL<\/jats:styled-content>,<jats:italic> P<\/jats:italic>\u00a0=\u00a00.001), 120\u2010min insulin concentration (101.86 [15.70] <jats:styled-content style=\"fixed-case\">mU<\/jats:styled-content>\/L vs 72.60 [11.36] <jats:styled-content style=\"fixed-case\">mU<\/jats:styled-content>\/L, <jats:italic>P<\/jats:italic>\u00a0=\u00a00.026), HbA1c (5.60 [0.06]% vs 5.40 [0.05]%, <jats:italic>P<\/jats:italic>\u00a0=\u00a00.001), homeostasis model assessment of insulin resistance (3.57 [0.45] vs 2.62 [0.24], <jats:italic>P<\/jats:italic>\u00a0=\u00a00.021) and Matsuda Index (7.7 [0.41] vs 9.2 [0.4], <jats:italic>P<\/jats:italic>\u00a0=\u00a00.001) significantly improved in the alendronate\u2010treated group. There were more statistically significant reductions in fasting plasma glucose (\u22128.2 [8.63] mg\/<jats:styled-content style=\"fixed-case\">dL<\/jats:styled-content> vs \u22122.5 [14.26] mg\/<jats:styled-content style=\"fixed-case\">dL<\/jats:styled-content>,<jats:italic> P<\/jats:italic>\u00a0=\u00a00.002) and HbA1c (\u22120.2 [0.23]% vs \u22120.09 [0.26]%, <jats:italic>P<\/jats:italic>\u00a0=\u00a00.015) observed in the alendronate\u2010treated group than the placebo group during the study course, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Administration of 70\u00a0mg\/week alendronate improves fasting plasma glucose, HbA1c and insulin indices in postmenopausal women.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jdi.12944","type":"journal-article","created":{"date-parts":[[2018,9,29]],"date-time":"2018-09-29T12:54:18Z","timestamp":1538225658000},"page":"731-737","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Alendronate improves fasting plasma glucose and insulin sensitivity, and decreases insulin resistance in prediabetic osteopenic postmenopausal women: A randomized triple\u2010blind clinical trial"],"prefix":"10.1111","volume":"10","author":[{"given":"Maryam","family":"Karimi Fard","sequence":"first","affiliation":[{"name":"Isfahan Endocrine and Metabolism Research Center Isfahan University of Medical Sciences Isfahan Iran"},{"name":"Rafsanjan University of Medical Sciences Rafsanjan Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7550-1198","authenticated-orcid":false,"given":"Ashraf","family":"Aminorroaya","sequence":"additional","affiliation":[{"name":"Isfahan Endocrine and Metabolism Research Center Isfahan University of Medical Sciences Isfahan Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Kachuei","sequence":"additional","affiliation":[{"name":"Isfahan Endocrine and Metabolism Research Center Isfahan University of Medical Sciences Isfahan Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Reza","family":"Salamat","sequence":"additional","affiliation":[{"name":"Department of Medical Physics and Medical Engineering Isfahan University of Medical Sciences Isfahan Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moluk","family":"Hadi Alijanvand","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics School of Health Isfahan University of Medical Sciences Isfahan Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sima","family":"Aminorroaya Yamini","sequence":"additional","affiliation":[{"name":"Department of Engineering and Mathematics Sheffield Hallam University Sheffield UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansoor","family":"Karimifar","sequence":"additional","affiliation":[{"name":"Isfahan Rheumatology Research Center Isfahan University of Medical Sciences Isfahan Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Awat","family":"Feizi","sequence":"additional","affiliation":[{"name":"Isfahan Endocrine and Metabolism Research Center Isfahan University of Medical Sciences Isfahan Iran"},{"name":"Department of Epidemiology and Biostatistics School of Health Isfahan University of Medical Sciences Isfahan Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massoud","family":"Amini","sequence":"additional","affiliation":[{"name":"Isfahan Endocrine and Metabolism Research Center Isfahan University of Medical Sciences Isfahan Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,10,23]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.hjr.0000368191.86614.5a"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc07-0959"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-S081"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00503.2006"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60766-7"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.20.4.537"},{"key":"e_1_2_7_8_1","first-page":"289","article-title":"Definition of prediabetes","volume":"95","author":"Buysschaert M","year":"2011","journal-title":"Med Clin"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-1939"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.7812\/TPP\/14-002"},{"key":"e_1_2_7_11_1","first-page":"173","article-title":"Therapeutic interventions to reduce the risk of progression from prediabetes to type 2 diabetes mellitus","volume":"10","author":"McLellan KC","year":"2014","journal-title":"Ther Clin Risk Manag"},{"key":"e_1_2_7_12_1","unstructured":"KanisJA.Assessment of osteoporosis at the primary health care level. WHO Collaborating Centre for Metabolic Bone Diseases. WHO Collaborating Centre for Metabolic Bone Diseases 2007."},{"key":"e_1_2_7_13_1","first-page":"S164","article-title":"Osteoporosis and the burden of osteoporosis\u2010related fractures","volume":"17","author":"Dempster DW","year":"2011","journal-title":"Am J Manag Care"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.4065\/83.9.1032"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-010-9364-1"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2008.03.006"},{"key":"e_1_2_7_17_1","first-page":"252","article-title":"Effects of bisphosphonates on lipid metabolism","volume":"29","author":"Guney E","year":"2008","journal-title":"Neuro Endocrinol Lett"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-3481"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-011-9515-z"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2010.06.003"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI39901"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0123279"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.10.2.238"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.27.6.1487"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0711119105"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2007.05.047"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2008.10.031"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.24929"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.1865"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/MAJ.0b013e3181db6dfe"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.27.7.1547"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.abb.2010.07.030"}],"container-title":["Journal of Diabetes Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdi.12944","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdi.12944","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdi.12944","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdi.12944","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T19:56:12Z","timestamp":1694375772000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdi.12944"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,23]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["10.1111\/jdi.12944"],"URL":"https:\/\/doi.org\/10.1111\/jdi.12944","archive":["Portico"],"relation":{},"ISSN":["2040-1116","2040-1124"],"issn-type":[{"value":"2040-1116","type":"print"},{"value":"2040-1124","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,23]]},"assertion":[{"value":"2018-03-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-09-18","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-10-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}